Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Conditions: Pancreatic Cancer
Interventions: Drug: NP137
Sponsors: Nabeel Badri; NETRIS Pharma
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 13, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments